Ignite Creation Date:
2024-05-05 @ 11:54 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00164749
Status:
COMPLETED
Last Update Posted:
2008-04-30
First Post:
2005-09-09
Brief Title:
A Pilot Study of Curcumin and Ginkgo for Treating Alzheimers Disease
Sponsor:
Chinese University of Hong Kong
Organization:
Chinese University of Hong Kong
Study Overview
Official Title:
A Pilot Study of Curcumin and Ginkgo for Treating Alzheimers Disease
Status:
COMPLETED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to develop procedures for testing the effectiveness of curcumin on slowing Alzheimers disease AD progression
Detailed Description:
A double-blind randomized clinical trial of 30 subjects will be carried out to develop procedures for testing the effectiveness of curcumin on slowing Alzheimers disease AD progression Curcumin is a polyphenolic molecule extracted from turmeric and is widely and safely used as a yellow food coloring Because of its strong anti-inflammatory activity curcumin was tested in animal models of AD where it significantly reduced levels of brain amyloid oxidized proteins and isoprostanes and prevented cognitive deficits AD patients will receive placebo 1 g or 4 g of curcumin daily for six months All patients will also receive 120 mg ginkgo leaf extract daily At 0 1 3 and 6 months of the study a cognitive test will be performed and blood samples will be analyzed for levels of isoprostane amyloid beta protein metals and cholesterol Curcumin and its metabolites will be measured in blood at 1 month The primary objective for this first human study of curcumin in AD is to examine safety and procedures for a possible larger trial testing curcumin against AD The secondary objective is to determine whether curcumin affects biochemical measures and if so which dose is most effective The tertiary objective is to determine whether curcumin slows cognitive decline in AD This study may lead to inexpensive treatment that delays progression of AD
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None